Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report; 2022. Available from: https://goldcopd.org/archived-reports/. Accessed April 4, 2022.
   Google Scholar
• World Health Organization. The top 10 causes of death; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed April 4, 2022.
   Google Scholar
• Office for Health Improvement & Disparities. Inhale - INteractive Health Atlas of Lung conditions in England; 2022. Available from: https://fingertips.phe.org.uk/profile/inhale/data#page/1/gid/8000008/pat/159/par/K02000001/ati/15/are/E92000001/yrr/1/cid/4/tbm/1. Accessed April 4, 2022.
   Google Scholar
• British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics; 2022. Available from: https://statistics.blf.org.uk/copd. Accessed April 4, 2022.
   Google Scholar
• McLean S, Hoogendoorn M, Hoogenveen RT, et al. Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Sci Rep. 2016;6:31893. doi:10.1038/srep31893
   PubMed Web of Science ®Google Scholar
• Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Madrazo Pérez M. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. 2021;11(1):31. doi:10.1186/s13561-021-00329-9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Health and social care directorate. Quality standards and indicators briefing paper; 2015. Available from: https://www.nice.org.uk/guidance/qs10/documents/briefing-paper#:~:text=One%20in%20eight%20(130%2C000)%20emergency,be%20readmitted%20within%20three%20months. Accessed April 4, 2022.
   Google Scholar
• de Nigris E, McEwan P, Marshall J, Holmgren U, Foos V. POSB65 Economic burden of COPD in the United Kingdom (2021–2040) estimated with the COPD Health Outcome Policy and Intervention (CHOPIN) model. Value Health. 2022;25(Suppl 1):S72‒S73.
   Web of Science ®Google Scholar
• Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555. doi:10.7326/0003-4819-146-8-200704170-00152
   PubMed Web of Science ®Google Scholar
• Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007;20(5):556–561.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Crater GD, Morris AN, Emmett AH, O’Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101. doi:10.1016/j.rmed.2011.09.002
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology. 2011;16(1):95–101. doi:10.1111/j.1440-1843.2010.01869.x
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382–389.
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–750. doi:10.1164/rccm.200904-0492OC
   PubMed Web of Science ®Google Scholar
• Usmani OS, Hickey AJ, Guranlioglu D, et al. The impact of inhaler device regimen in patients with asthma or COPD. J Allergy Clin Immunol Pract. 2021;9(8):3033–3040. doi:10.1016/j.jaip.2021.04.024
   PubMed Web of Science ®Google Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823
   PubMed Web of Science ®Google Scholar
• Halpin DM, Kendall R, Shukla S, et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial. Int J Chron Obstruct Pulmon Dis. 2022;17:2745–2755. doi:10.2147/COPD.S370577
   PubMed Web of Science ®Google Scholar
• Bansal S, Anderson M, Anzueto A, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):29.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Baker T, Risebrough NA, et al. Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
   PubMed Web of Science ®Google Scholar
• Exuzides A, Colby C, Briggs AH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37(4):453–468.
   PubMed Web of Science ®Google Scholar
• Risebrough NA, Briggs A, Baker TM, et al. Validating a model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–A561. doi:10.1016/j.jval.2014.08.1852
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-122
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.00111707
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013; 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-The-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed August 1, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary (BNF); 2022. Available from: https://bnf.nice.org.uk/. Accessed April 4, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive disease in over 16s: diagnosis and management. NICE guideline NG115; 2018. Available from: https://www.nice.org.uk/guidance/NG115. Accessed April 4, 2022.
   Google Scholar
• IQVIA [Data on file]. COPD Drug Market Share Data - provided by GSK. 2020.
   Google Scholar
• Office for National Statistics. CPIH index 00: all items 2015=100; 2022. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/l522/mm23. Accessed April 4, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive disease in over 16s: diagnosis and management: economic model report; 2018. Available from: https://www.nice.org.uk/guidance/ng115/documents/economic-report. Accessed August 18, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing. NICE guideline NG114; 2018. Available from: https://www.nice.org.uk/guidance/ng114. Accessed April 4, 2022.
   Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/COPD.S216072
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline [Data on file]. IMPACT clinical trial supplementary materials; 2017.
   Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–2020.
   PubMedGoogle Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. PharmacoEconomics. 1998;13(1 Pt 1):1–7. doi:10.2165/00019053-199813010-00001
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. EARN01: average weekly earnings; 2022. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/averageweeklyearningsearn01/current. Accessed April 4, 2022.
   Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.
   PubMed Web of Science ®Google Scholar
• ICON plc [Data on file]. Global health economics, and outcomes research and epidemiology. Cost-effectiveness model for UMEC/VI in COPD using the EMAX trial: UK National Health Services perspective. 2021.
   Google Scholar
• Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391–401. doi:10.2147/COPD.S173901
   PubMed Web of Science ®Google Scholar
• Martin A, Shah D, Ndirangu K, et al. Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Res. 2022;8(1):00333–2021. doi:10.1183/23120541.00333-2021
   PubMedGoogle Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632.
   PubMed Web of Science ®Google Scholar
• Schroeder M, Shah D, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective. Respir Med X. 2019;1:100008.
   Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480–2020. doi:10.1183/23120541.00480-2020
   PubMedGoogle Scholar
• European Medicines Agency. Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed [summary of product characteristics]; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-ellipta-epar-product-information_en.pdf. Accessed August 2, 2022.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar